Pharmafile Logo
Pharmafocus logo
Advanced Search

Medical Communications

Showing 15 posts of 6408 posts found.

Adaptimmune receives US FDA Accelerated Approval for engineered cell therapy for a solid tumour

August 2, 2024 Medical Communications Adaptimmune, Oncology, accelerated approval, engineered cell therapy, oncology, synovial sarcoma

Adaptimmune Therapeutics has announced today that the US Food and Drug Administration (FDA) has given accelerated approval for TECELRA (afamitresgene …
News

INDEPENDENT PARSORTIX STUDY HIGHLIGHTS BENEFITS OF COMBINED DNA ANALYSIS IN MELANOMA

August 1, 2024 Medical Communications, Research and Development Angle, Internal Medicine, Oncology, Parsortix, melanoma

Multi-analyte approach has potential to guide personalised cancer care CTC mutation profiles associated with more aggressive disease ANGLE plc. a …
News
Press release

Drug discovery and development partnership announced between Apollo Therapeutics and Oxford University

July 31, 2024 Clinical Research, Medical Communications, Research and Development Apollo Therapeutics, Internal Medicine, Microbiology, drug development, drug discovery, research

Portfolio therapeutics company Apollo Therapeutics has announced earlier this week that it will provide capital and expertise to Oxford University’s …
News

FDA release statement exercising caution around dosing errors associated with compounded injectable semaglutide products

July 31, 2024 Media Relations, Medical Communications, Pharmacovigilance, US Healthcare & Trade Press FDA, Gastrointestinal tract, compunded injectable, dosage, hospitalisation, pharmaceutical, warning

This week, the US Food and Drug Administration (FDA) and have issued warnings regarding dosing errors associated with compounded injectable …
News

BioAtla gains FDA Fast Track Designation for ozuriftamab vedotin

July 25, 2024 Medical Communications BioAtla, FDA, Oncology, fast track designation, ozuriftamab vedotin

BioAtla has announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to ozuriftamab vedotin, …
News

J&J seeks FDA approval of Spravato as monotherapy for treatment-resistant depression

July 24, 2024 Medical Communications J&J, Johnson & Johnson, Neurology, Spravato, treatment-resistant depression

Johnson & Johnson (J&J) has announced that it has submitted a supplemental New Drug Application (sNDA) to the US Food …
News

60 Degrees Pharmaceuticals signs clinical trial agreements with sites for babesiosis study

July 22, 2024 Medical Communications 60 Degrees Pharmaceuticals, Pharmacy, babesiosis, clinical trials

60 Degrees Pharmaceuticals has announced that it has signed clinical trial agreements with all three of its planned trial sites …
News

GSK’s application for Blenrep for MM treatment accepted for EMA review

July 19, 2024 Medical Communications Blenrep, EMA, GSK, Oncology

GSK has announced that the European Medicines Agency (EMA) has accepted the marketing authorisation application (MAA) for Blenrep (belantamab mafodotin) …
News

FDA accepts Atara Biotherapeutics’ Tab-Cel for priority review

July 18, 2024 Medical Communications Atara Biotherapeutics, FDA, Virology, priority review

Atara Biotherapeutics has announced that the US Food and Drug Administration (FDA) has accepted the filing of its Biologics License …
News

China’s NMPA accepts Everest Medicines’ Nefecon supplementary application

July 18, 2024 Medical Communications China, Everest Medicines, NMPA, Nephrology

Everest Medicines has announced that China’s National Medical Products Administration (NMPA) has accepted the submission of a supplemental New Drug …
News

NICE recommends digital tech for ADHD diagnosis in children and young people

July 16, 2024 Medical Communications ADHD, Diagnostics, NICE

The National Institute for Health and Care Excellence (NICE) has announced that its diagnostics advisory committee has recommended the QbTest …
News

Biophytis gains IND approval from FDA for obesity study

July 11, 2024 Medical Communications Biophytis, IND, Obesity, clinical trial, obesity

Biophytis has announced that it has received investigational new drug (IND) approval from the US Food and Drug Administration (FDA) …
News

Roche gains CE Mark for AI glucose monitoring system for diabetes management

July 9, 2024 Medical Communications AI, Diabetes, Roche, diabetes, glucose monitoring

Roche has announced that it has received the CE Mark for its Accu-Chek SmartGuide continuous glucose monitoring (CGM) solution.
News

AstraZeneca’s Tagrisso gains EU approval for lung cancer treatment

July 8, 2024 Medical Communications AstraZeneca, Oncology, Tagrisso, lung cancer

AstraZeneca has announced that the EU’s European Commission (EC) has approved Tagrisso (osimertinib), with the addition of pemetrexed and platinum-based …
News

Eli Lilly’s Kisunla approved by FDA for Alzheimer’s treatment

July 3, 2024 Medical Communications Alzheimer's, Eli Lilly, Kisunla, Neurology

Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Kisunla (donanemab-azbt, 350mg/20ml once-monthly injection for …
News
The Gateway to Local Adoption Series

Latest content

Rhythm AI’s STAR Apollo system receives FDA clearance for atrial fibrillation

February 12, 2026

iOrganBio appoints Karol Jarzabek as Chief Operating Officer

February 12, 2026

Ensera Design expands UK leadership team with new senior appointments

February 11, 2026

Infinitopes announces $15.4m in additional seed funding to advance cancer vaccine

February 11, 2026

Angelini Pharma appoints Roberto Scrivo as Chief of External Affairs, Communication and Sustainability Officer

February 10, 2026